GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » FCF Margin %

Neuraxis (Neuraxis) FCF Margin % : -208.19% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Neuraxis's Free Cash Flow for the three months ended in Mar. 2024 was $-1.35 Mil. Neuraxis's Revenue for the three months ended in Mar. 2024 was $0.65 Mil. Therefore, Neuraxis's FCF Margin % for the quarter that ended in Mar. 2024 was -208.19%.

As of today, Neuraxis's current FCF Yield % is -35.62%.

The historical rank and industry rank for Neuraxis's FCF Margin % or its related term are showing as below:

NRXS' s FCF Margin % Range Over the Past 10 Years
Min: -325.16   Med: -151.89   Max: -82.14
Current: -325.16


During the past 4 years, the highest FCF Margin % of Neuraxis was -82.14%. The lowest was -325.16%. And the median was -151.89%.

NRXS's FCF Margin % is ranked worse than
60.48% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs NRXS: -325.16


Neuraxis FCF Margin % Historical Data

The historical data trend for Neuraxis's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis FCF Margin % Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Margin %
-215.91 -82.14 -87.86 -275.04

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.39 -97.52 -599.37 -498.31 -208.19

Competitive Comparison of Neuraxis's FCF Margin %

For the Biotechnology subindustry, Neuraxis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Neuraxis's FCF Margin % falls into.



Neuraxis FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Neuraxis's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-6.766/2.46
=-275.04 %

Neuraxis's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-1.347/0.647
=-208.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuraxis FCF Margin % Related Terms

Thank you for viewing the detailed overview of Neuraxis's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis (Neuraxis) Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042